Expression of vascular endothelial growth factors and their receptors in human endometrium from women experiencing abnormal bleeding patterns after prolonged use of a levonorgestrel-releasing intrauterine system

Human Reproduction

Volumn 20, Issue 5, 2005, Pages 1410-1417

  Möller, Björn ^a   Rönnerdag, Maria ^a   Wang, Guimin ^a   Odlind, Viveca ^a   Olovsson, Matts ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Angiogenesis; Endometrium; Levonorgestrel releasing intrauterine system; Menstrual bleeding disturbances; Vascular endothelial growth factors

Indexed keywords

ESTRADIOL; LEVONORGESTREL; PROGESTERONE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE REMOVAL; DRUG DELIVERY SYSTEM; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOTHELIUM CELL; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MENSTRUATION DISORDER; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENT DISEASE; SCORING SYSTEM; STROMA CELL; VASCULAR FRAGILITY;

EID: 20344369981     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deh810     Document Type: Article

References (52)

1. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K and Stacker SA (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95,548-553.
2. Andersson JK and Rybo G (1990) Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 97, 690-694.
3. Andersson K, Odlind V and Rybo G (1994) Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 49,56-72.
4. Backman T, Huhtala S, Blom T, Luoto R, Rauramo I and Koskenvuo M (2000) Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. Br J Obstet Gynaecol 107,335-339.
5. Barbosa I, Olsson SE, Odlind V, Goncalves T and Coutinho E (1995) Ovarian function after seven years' use of a levonorgestrel IUD. Adv Contracept 11,85-95.
6. Belsey EM (1991) Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Adv Contraception 7,257-270.
7. Belsey EM (1988) The analysis of menstrual bleeding patterns: a review. Contraception 38,129-156.
8. Charnock-Jones DS, Macpherson AM, Archer DF, Leslie S, Makkink WK, Sharkey M and Smith SK (2000) The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum Reprod 15(Suppl 3),85-95.
9. Critchley HO, Brenner RM, Henderson TA, Williams K, Nayak NR, Slayden OD, Millar MR and Saunders PT (2001) Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J Clin Endocrinol Metab 86,1370-1378.
10. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N and Williams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255,989-991.
11. Ferrara N and Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161,851-858.
12. Folkman J and Klagsbrun M (1987) Angiogenic factors. Science 235, 442-447.
13. Gambino LS, Wreford NG, Bertram JF, Dockery P, Lederman F and Rogers PA (2002) Angiogenesis occurs by vessel elongation in proliferative phase human endometrium. Hum Reprod 17,1199-1206.
14. Giudice LC (1994) Growth factors and growth modulators in human uterine endometrium: their potential relevance to reproductive medicine. Fertil Steril 61,1-17.
15. Gu Z, Zhu P, Luo H, Zhu X, Zhang G and Wu S (1995) A morphometric study on the endometrial activity of women before and after one year with LNG-IUD in situ. Contraception 52,57-61.
16. Hague S, MacKenzie IZ, Bicknell R and Rees MC (2002) In-vivo angiogenesis and progestogens. Hum Reprod 17,786-793.
17. Hanahan D (1997) Signaling vascular morphogenesis and maintenance. Science 277,48-50.
18. Hickey M, Dwarte D and Fraser IS (1998) Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use. Hum Reprod 13,3190-3196.
19. Iruela-Arispe ML, Rodriguez-Manzaneque JC and Abu-Jawdeh G (1999) Endometrial endothelial cells express estrogen and progesterone receptors and exhibit a tissue specific response to angiogenic growth factors. Microcirculation 6,127-140.
20. Johannisson E (1990) Endometrial morphology during the normal cycle and under the influence of contraceptive steroids. In d'Arecangues C, Fraser IS, Newton JR, and Odlind V (eds) Contraception and mechanisms of endometrial bleeding. Cambridge University Press, Cambridge, UK, pp.53-80.
21. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N and Alitalo K (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15,290-298.
22. Jussila L, Valtola R, Partanen TA, Salven P, Heikkila P, Matikainen MT, Renkonen R, Kaipainen A, Detmar M, Tschachler E et al. (1998) Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res 58,1599-1604.
23. Krüssel JS, Casan EM, Raga F, Hirchenhain J, Wen Y, Huang HY, Bielfeld P and Polan ML (1999) Expression of mRNA for vascular endothelial growth factor transmembraneous receptors Flt1 and KDR, and the soluble receptor sflt in cycling human endometrium. Mol Hum Reprod 5,452-458.
24. Laoag-Fernandez JB, Maruo T, Pakarinen P, Spitz IM and Johansson E (2003) Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis. Hum Reprod 18,694-699.
25. Lecce G, Meduri G, Ancelin M, Bergeron C and Perrot-Applanat M (2001) Presence of estrogen receptor beta in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J Clin Endocrinol Metab 86,1379-1386.
26. Lee J, Gray A, Yuan J, Luoh SM, Avraham H and Wood WI (1996) Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93, 1988-1992.
27. Möller B, Rasmussen C, Lindblom B and Olovsson M (2001) Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle. Mol Hum Reprod 7,65-72.
28. Möller B, Lindblom B and Olovsson M (2002) Expression of the vascular endothelial growth factors B and C and their receptors in human endometrium during the menstrual cycle. Acta Obstet Gynecol Scand 81, 817-824.
29. Nilsson CG, Lahteenmaki PL and Luukkainen T (1984) Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 41,52-55.
30. Odlind V (1998) Disturbances of bleeding with intrauterine contraceptive devices and hormonal intrauterine systems. In Cameron IT, Fraser IS, and Smith SK (eds) Clinical disorders of the endometrium and menstrual cycle. Oxford University Press, Oxford, UK, pp. 390-398.
31. Odlind V and Fraser IS (1990) Contraception and menstrual bleeding disturbance: a clinical overview. In d'Arecangues C, Fraser IS, Newton JR, and Odlind V (eds) Contraception and mechanisms of endometrial bleeding. Cambridge University Press, Cambridge, UK, pp. 5-31.
32. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K and Eriksson U (1996) Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93,2576-2581.
33. Pakarinen PI, Lahteenmaki P, Lehtonen E and Reima I (1998) The ultrastructure of human endometrium is altered by administration of intrauterine levonorgestrel. Hum Reprod 13,1846-1853.
34. Quinn TP, Peters KG, de Vries C, Ferrara N and Williams LT (1993) Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90,7533-7537.
35. Rogers PA (1996) Endometrial vasculature in Norplant users. Hum Reprod 11 (Suppl 2),45-50.
36. Rogers PA, Au CL and Affandi B (1993) Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum Reprod 8,1396-1404.
37. Rogers PAW and Gargett CE (1998) Endometrial angiogenesis. Angiogenesis 2,287-294.
38. Rönnerdag M and Odlind V (1999) Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 78,716-721.
39. Roopa BA, Loganath A and Singh K (2003) The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometrium. Hum Reprod 18,1809-1819.
40. Runic R, Schatz F, Wan L, Demopoulos R, Krikun G and Lockwood CJ (2000) Effects of norplant on endometrial tissue factor expression and blood vessel structure. J Clin Endocrinol Metab 85,3853-3859.
41. Saaristo A, Partanen TA, Arola J, Jussila L, Hytonen M, Makitie A, Vento S, Kaipainen A, Malmberg H and Alitalo K (2000) Vascular endothelial growth factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal tumors. Am J Pathol 157,7-14.
42. Senthil D, Ghosh Choudhury G, Bhandari BK and Kasinath BS (2002) The type 2 vascular endothelial growth factor receptor recruits insulin receptor substrate-1 in its signaling pathway. Biochem J 368,49-56.
43. Smith SK (1998) Angiogenesis, vascular endothelial growth factor and the endometrium. Hum Reprod Update 4,509-519.
44. Smith SK (2001) Regulation of angiogenesis in the endometrium. Trends Endocrinol Metab 12,147-151.
45. Song JY, Markham R, Russell P, Wong T, Young L and Fraser IS (1995) The effect of high-dose medium- and long-term progestogen exposure on endometrial vessels. Hum Reprod 10,797-800.
46. Suvisaari J and Lahteenmaki P (1996) Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 54, 201-208.
47. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC and Abraham JA (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266,11947-11954.
48. Wollter-Svensson LO, Stadberg E, Andersson K, Mattsson LA, Odlind V and Persson I (1997) Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstet Gynecol Scand 76, 449-454.
49. Yamada Y, Nezu J, Shimane M and Hirata Y (1997) Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 42, 483-488.
50. Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Sakamoto A, Sakamoto T, Maruyama H et al. (2003) Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res 9,1361-1369.
51. Zhu P, Liu X, Luo H, Gu Z, Cheng J, Xu R, Lian S, Wu S and Wang J (1999) The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use. Hum Reprod 14,970-975.
52. Zhu PD, Luo HZ, Xu RH, Cheng J, Wu SC, Chen JH, Wu MZ and Wang XP (1989) The effect of intrauterine devices, the stainless steel ring, the copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium - a comparative study of three IUDs. A morphometric study of 96 cases. Contraception 40, 425-438.